Evotec SE (NASDAQ:EVO) Short Interest Update

Evotec SE (NASDAQ:EVO) saw a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 220,100 shares, a decline of 10.7% from the October 15th total of 246,500 shares. Based on an average trading volume of 138,900 shares, the days-to-cover ratio is currently 1.6 days. Approximately 0.1% of the company’s stock are sold short.

Hedge Funds Weigh In On Evotec

Several institutional investors have recently bought and sold shares of EVO. Cetera Advisors LLC acquired a new position in Evotec in the 1st quarter valued at $188,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Evotec during the 2nd quarter worth $87,000. DCF Advisers LLC boosted its position in shares of Evotec by 140.5% during the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after purchasing an additional 67,156 shares in the last quarter. Novo Holdings A S purchased a new stake in shares of Evotec during the 2nd quarter worth $71,183,000. Finally, Mediolanum International Funds Ltd purchased a new stake in shares of Evotec during the 3rd quarter worth $512,000. 5.81% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on EVO. Jefferies Financial Group cut shares of Evotec from a “buy” rating to a “hold” rating and cut their price objective for the stock from $8.70 to $3.80 in a report on Monday, October 7th. Morgan Stanley cut shares of Evotec from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $15.00 to $6.00 in a report on Monday, July 29th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Evotec in a report on Thursday, November 7th. Finally, Deutsche Bank Aktiengesellschaft cut shares of Evotec from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $5.93.

Evotec Trading Up 2.0 %

Shares of Evotec stock traded up $0.11 during trading on Monday, reaching $5.55. The company’s stock had a trading volume of 281,458 shares, compared to its average volume of 130,829. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09. The company has a 50-day moving average price of $3.66 and a two-hundred day moving average price of $4.19. Evotec has a fifty-two week low of $2.85 and a fifty-two week high of $12.00.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.